Patterns of care and outcomes of 417 ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).
Author(s) :
Moreau-Bachelard, C. [Auteur]
CRLCC René Gauducheau
Campion, L. [Auteur]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
CRLCC René Gauducheau
Toulmonde, M. [Auteur]
Institut Bergonié [Bordeaux]
Le Cesne, A. [Auteur]
Institut Gustave Roussy [IGR]
Brahmi, M. [Auteur]
Centre Léon Bérard [Lyon]
Italiano, A. [Auteur]
Institut Bergonié [Bordeaux]
Mir, O. [Auteur]
Institut Gustave Roussy [IGR]
Piperno-Neumann, S. [Auteur]
Institut Curie [Paris]
Laurence, V. [Auteur]
Institut Curie [Paris]
Firmin, N. [Auteur]
Institut de Recherche en Cancérologie de Montpellier [IRCM - U1194 Inserm - UM]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Duffaud, F. [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Chevreau, C. [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Bertucci, F. [Auteur]
Institut Paoli-Calmettes [IPC]
Narciso, B. [Auteur]
Hôpital Bretonneau
Dubray-Longeras, P. [Auteur]
Centre Jean Perrin [Clermont-Ferrand] [UNICANCER/CJP]
Delcambre, C. [Auteur]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC]
Saada-Bouzid, E. [Auteur]
Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] [UNICANCER/CAL]
Boudou-Rouquette, P. [Auteur]
Hôpital Cochin [AP-HP]
Soulie, P. [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Perrin, C. [Auteur]
CRLCC Eugène Marquis [CRLCC]
Blay, J. Y. [Auteur]
Centre Léon Bérard [Lyon]
Bompas, E. [Auteur]
CRLCC René Gauducheau
CRLCC René Gauducheau
Campion, L. [Auteur]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
CRLCC René Gauducheau
Toulmonde, M. [Auteur]
Institut Bergonié [Bordeaux]
Le Cesne, A. [Auteur]
Institut Gustave Roussy [IGR]
Brahmi, M. [Auteur]
Centre Léon Bérard [Lyon]
Italiano, A. [Auteur]
Institut Bergonié [Bordeaux]
Mir, O. [Auteur]
Institut Gustave Roussy [IGR]
Piperno-Neumann, S. [Auteur]
Institut Curie [Paris]
Laurence, V. [Auteur]
Institut Curie [Paris]
Firmin, N. [Auteur]
Institut de Recherche en Cancérologie de Montpellier [IRCM - U1194 Inserm - UM]
Penel, Nicolas [Auteur]

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Duffaud, F. [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Chevreau, C. [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Bertucci, F. [Auteur]
Institut Paoli-Calmettes [IPC]
Narciso, B. [Auteur]
Hôpital Bretonneau
Dubray-Longeras, P. [Auteur]
Centre Jean Perrin [Clermont-Ferrand] [UNICANCER/CJP]
Delcambre, C. [Auteur]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC]
Saada-Bouzid, E. [Auteur]
Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] [UNICANCER/CAL]
Boudou-Rouquette, P. [Auteur]
Hôpital Cochin [AP-HP]
Soulie, P. [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Perrin, C. [Auteur]
CRLCC Eugène Marquis [CRLCC]
Blay, J. Y. [Auteur]
Centre Léon Bérard [Lyon]
Bompas, E. [Auteur]
CRLCC René Gauducheau
Journal title :
European Society for Medical Oncology
Abbreviated title :
ESMO Open
Volume number :
7
Pages :
100402
Publication date :
2022-02-26
ISSN :
2059-7029
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Background
Synovial sarcoma (SS) occurs in both adult and pediatric patients. The primary aim of this study is to describe the outcomes, prognostic factors, and treatment of patients with metastatic SS within a nationwide ...
Show more >Background Synovial sarcoma (SS) occurs in both adult and pediatric patients. The primary aim of this study is to describe the outcomes, prognostic factors, and treatment of patients with metastatic SS within a nationwide cohort. Patients and methods All pediatric and adult patients with metastatic SS are registered in the French Sarcoma Group database. Data were collected from the national database https://conticabase.sarcomabcb.org/ up to March 2020. Descriptive and comparative analyses were conducted using SAS 9.4 and Stata Special Edition 16.1 software. Results Between January 1981 and December 2019, 417 patients with metastatic SS from 17 French sarcoma centers were included, including 64 (15.3%) under the age of 26 years. Median age was 42.5 years (range 9-87 years). The metastases were synchronous (cohort 1) or metachronous (cohort 2) in 18.9% (N = 79) and 81.1% (N = 338) patients, respectively. Median overall survival (OS) from the date of metastasis was 22.3 months (95% confidence interval 19.7-24.1 months). First-line chemotherapy without ifosfamide and/or doxorubicin was unfavorable for progression-free survival and OS (P < 0.001). Concerning cohort 1, young age, surgery of the primary tumor, and single metastatic site were independent favorable prognostic factors for OS. In cohort 2, surgery within an expert French Sarcoma Group center, absence of chemotherapy in the perioperative setting, the lungs as a single metastatic site, time to first metastasis >12 months, local therapy, and ifosfamide in the first metastatic line were independent favorable prognostic factors. Conclusions The outcome of patients with metastatic SS is influenced by local treatment, management in reference centers, and cytotoxic treatments given in the perioperative and metastatic setting.Show less >
Show more >Background Synovial sarcoma (SS) occurs in both adult and pediatric patients. The primary aim of this study is to describe the outcomes, prognostic factors, and treatment of patients with metastatic SS within a nationwide cohort. Patients and methods All pediatric and adult patients with metastatic SS are registered in the French Sarcoma Group database. Data were collected from the national database https://conticabase.sarcomabcb.org/ up to March 2020. Descriptive and comparative analyses were conducted using SAS 9.4 and Stata Special Edition 16.1 software. Results Between January 1981 and December 2019, 417 patients with metastatic SS from 17 French sarcoma centers were included, including 64 (15.3%) under the age of 26 years. Median age was 42.5 years (range 9-87 years). The metastases were synchronous (cohort 1) or metachronous (cohort 2) in 18.9% (N = 79) and 81.1% (N = 338) patients, respectively. Median overall survival (OS) from the date of metastasis was 22.3 months (95% confidence interval 19.7-24.1 months). First-line chemotherapy without ifosfamide and/or doxorubicin was unfavorable for progression-free survival and OS (P < 0.001). Concerning cohort 1, young age, surgery of the primary tumor, and single metastatic site were independent favorable prognostic factors for OS. In cohort 2, surgery within an expert French Sarcoma Group center, absence of chemotherapy in the perioperative setting, the lungs as a single metastatic site, time to first metastasis >12 months, local therapy, and ifosfamide in the first metastatic line were independent favorable prognostic factors. Conclusions The outcome of patients with metastatic SS is influenced by local treatment, management in reference centers, and cytotoxic treatments given in the perioperative and metastatic setting.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CHU Lille
CHU Lille
Submission date :
2023-11-15T04:33:20Z
2024-04-26T08:33:42Z
2024-04-26T08:33:42Z
Files
- document
- Open access
- Access the document